What Peptides Help with Longevity?

← Back to Clinical Articles

Article: What Peptides Help with Longevity?  |  Category: Peptide Therapy  |  Authored by: Brian Lamkin, DO

The Aging Mechanisms That Longevity Peptides Target

The hallmarks of aging as defined in the scientific literature include mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, stem cell exhaustion, loss of proteostasis, and altered intercellular communication^[1]. Longevity peptides do not target "aging" as a vague concept. They target specific, measurable hallmarks with defined mechanisms of action. Growth hormone secretagogues address the decline in anabolic and repair signaling (stem cell exhaustion, loss of proteostasis). Mitochondrial peptides address energy production decline (mitochondrial dysfunction). Tissue repair peptides address the loss of regenerative capacity. Immune peptides address immunosenescence (altered intercellular communication). The clinical value of peptides in longevity medicine is their precision: each targets a specific hallmark, and the combination addresses the multi-mechanism nature of biological aging.

CJC-1295/Ipamorelin: Restoring the Growth Hormone Axis

Growth hormone is the body's primary anabolic and repair signal. It maintains lean muscle mass, bone mineral density, skin thickness and elasticity, cognitive function, immune surveillance, and recovery capacity. GH secretion declines approximately 14 percent per decade after age 30^[2]. By age 60, most adults have lost 75 percent of their youthful GH output. This decline directly contributes to sarcopenia (muscle loss), osteopenia, visceral fat accumulation, thinning skin, reduced recovery, cognitive slowing, and impaired immune function. CJC-1295 (a GHRH analog with extended half-life) combined with ipamorelin (a selective GHRP that acts through the ghrelin receptor) stimulates the pituitary to produce GH in physiological pulses that mimic the natural nocturnal GH surge. Administered as a subcutaneous injection at bedtime, the combination augments the natural GH pulse without the risks of direct GH injection (which bypasses pituitary regulation and can produce supraphysiological levels). Clinical outcomes measured by IGF-1 optimization include improved body composition (reduced visceral fat, increased lean mass), improved sleep quality, improved skin appearance, enhanced exercise recovery, and improved cognitive clarity. Typical cycles: 3 to 6 months on, 1 to 2 months off.

MOTS-c: The Mitochondrial Longevity Peptide

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA that has emerged as one of the most significant longevity peptides in current research^[3]. MOTS-c activates AMPK (the cellular energy sensing and repair pathway), improves insulin sensitivity, enhances mitochondrial function, protects against age-related metabolic decline, and has been shown to improve exercise capacity in aging animal models. MOTS-c is sometimes called an "exercise mimetic" because it activates many of the same cellular pathways that exercise activates: AMPK signaling, improved glucose utilization, enhanced fatty acid oxidation, and mitochondrial biogenesis. MOTS-c levels decline naturally with age, correlating with the metabolic decline and insulin resistance progression seen in aging. Supplementation aims to restore MOTS-c signaling to support metabolic health, exercise capacity, and mitochondrial function in aging adults. Administration: subcutaneous injection, typically 5mg 3 to 5 times per week in 8 to 12 week cycles.

BPC-157: Maintaining Tissue Repair Capacity

One of the defining features of aging is declining tissue repair capacity: injuries heal more slowly, tendons become more susceptible to damage, gut barrier function deteriorates, and the angiogenic response (new blood vessel formation at repair sites) weakens^[4]. BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice that promotes tissue repair through angiogenesis upregulation, growth factor expression, and anti-inflammatory mechanisms. In a longevity context, BPC-157 is used to maintain the regenerative capacity that naturally declines with age: accelerating recovery from exercise and injury, supporting gut barrier integrity, and reducing the cumulative inflammatory burden from chronic tissue damage. It is also valuable for patients beginning or intensifying exercise programs, where the increased musculoskeletal demand may exceed the aging body's repair capacity. Administration: subcutaneous injection 250 to 500mcg daily for 4 to 8 week cycles, or oral 500mcg twice daily for gut-specific applications.

Thymosin Alpha-1: Addressing Immunosenescence

The thymus gland, which is responsible for T-cell maturation and immune system training, involutes progressively after puberty. By age 50, most adults have significantly reduced thymic function, producing fewer naive T-cells and relying increasingly on memory T-cells with narrowing immune repertoire. This immunosenescence reduces the ability to respond to novel infections, decreases cancer immune surveillance, reduces vaccine efficacy, and increases susceptibility to autoimmune dysregulation. Thymosin alpha-1 is a 28-amino-acid thymic peptide that modulates immune function through dendritic cell maturation, T-cell activation, and NK cell enhancement. In a longevity context, it partially compensates for thymic involution by supporting the immune functions that depend on thymic output. Clinically, patients on thymosin alpha-1 report fewer infections, improved recovery from illness, and in some cases, improved response to vaccination. Administration: subcutaneous injection 1.6mg 2 to 3 times per week.

Epitalon: The Telomere Peptide

Epitalon (epithalon, epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the naturally occurring pineal peptide epithalamin. It has been studied primarily in Russian aging research and has demonstrated telomerase activation in human cell cultures. Telomeres (the protective caps on chromosome ends) shorten with each cell division, and critically short telomeres trigger cellular senescence or apoptosis. Telomerase is the enzyme that can lengthen telomeres, and its activity is suppressed in most somatic cells. Epitalon has shown ability to activate telomerase in human somatic cells, potentially extending replicative capacity. Additionally, epitalon has demonstrated melatonin production support (relevant because pineal melatonin production declines with age), antioxidant properties, and neuroendocrine normalization in aging models. Clinical evidence in humans is limited to small studies and case series. It is used in longevity protocols at 5 to 10mg subcutaneously daily for 10 to 20 day cycles, typically 1 to 2 times per year.

SS-31 (Elamipretide): Targeting Mitochondrial Membrane Function

SS-31 is a cell-permeable peptide that concentrates in the inner mitochondrial membrane where it stabilizes cardiolipin, the phospholipid essential for electron transport chain complex organization and efficient ATP production. With aging, cardiolipin content and composition in the inner mitochondrial membrane change, reducing electron transport efficiency and increasing reactive oxygen species (ROS) production. SS-31 stabilizes cardiolipin, improves electron transport chain function, reduces mitochondrial ROS production, and has demonstrated benefits in models of heart failure, mitochondrial dysfunction, and age-related skeletal muscle decline. SS-31 is in clinical trials for several age-related conditions (Barth syndrome, age-related macular degeneration, heart failure). In longevity practice, it is used alongside MOTS-c to address mitochondrial aging from two complementary angles: MOTS-c activates AMPK and mitochondrial biogenesis (making new mitochondria), while SS-31 improves the function of existing mitochondria.

The Foundation Must Come First

Longevity peptides are precision tools that amplify a healthy foundation. They do not substitute for one. Before initiating longevity peptide therapy, the following must be optimized: metabolic health (fasting insulin below 5 uIU/mL, HOMA-IR below 1.0, HbA1c below 5.4), body composition (adequate lean mass, reducing visceral fat), hormonal balance (thyroid optimization with Free T3 in the upper third, testosterone optimization when deficient, DHEA-S repletion), inflammation (hs-CRP below 1.0, omega-3 optimization), sleep (7 to 9 hours with optimized sleep architecture for GH secretion), exercise (resistance training 3 to 4 times per week for GH stimulation, insulin sensitization, and sarcopenia prevention), and nutrition (adequate protein, low glycemic structure, micronutrient repletion). A GH secretagogue peptide produces significantly better outcomes in a patient with optimized insulin sensitivity, adequate sleep, and consistent resistance training than in a patient who is insulin-resistant, sleep-deprived, and sedentary. The peptide amplifies the signal. The foundation determines the amplitude.

Monitoring a Longevity Peptide Protocol

Objective monitoring distinguishes evidence-based longevity medicine from anti-aging marketing. For GH secretagogues: IGF-1 at baseline, 6 weeks, and every 3 to 6 months (target: upper third of age-adjusted reference range). Fasting insulin and HbA1c at baseline and 3 months to monitor for GH-mediated insulin resistance. Body composition (DEXA) at baseline and 6 months. For MOTS-c: fasting insulin and HOMA-IR at baseline and 8 weeks (expect improvement). Exercise capacity assessment (VO2 max or timed functional tests). For all protocols: hs-CRP and DHEA-S as general aging biomarkers. Symptom tracking (energy, recovery, cognitive function, sleep quality, body composition changes). The goal is measurable improvement in specific biomarkers and functional outcomes, documented by data at every monitoring interval.

The Lamkin Clinic Approach to Longevity Peptide Therapy

At The Lamkin Clinic, longevity peptide therapy is prescribed within a comprehensive biological age assessment framework. The evaluation includes IGF-1 (GH axis), DHEA-S (adrenal and neurosteroid reserve), fasting insulin and HOMA-IR (metabolic aging), hs-CRP (inflammaging), vitamin D (immune and bone health), full thyroid panel, sex hormone panel, and body composition analysis. Peptide selection targets the specific aging mechanisms identified as most active in the individual patient. Foundational optimization is required before peptide initiation. Monitoring occurs at defined intervals with objective endpoints. The goal is to close the gap between chronological and biological age using the minimum effective intervention, confirmed by data, within a comprehensive protocol that addresses metabolism, hormones, inflammation, mitochondrial function, and body composition together.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Lopez-Otin C, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
2. [2]Ghigo E, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1999;141(5):445-460.
3. [3]Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
4. [4]Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865.